Search

In this Q&A, medical oncologist Emily Feld talks about how metastatic cancer is diagnosed and treated at MSK.

… Tuesday, July 26, 2022 Many tumors can be eliminated with surgery , chemotherapy , radiation , and other treatments. But once cancer spreads, or metastasizes, to other parts of the body, it becomes much harder to stop. In this Q&A, medical oncologist Emily Feld talks about how metastatic cancer is diagnosed

Memorial Sloan Kettering researchers have discovered how a common bacterium can evolve to become more mobile and easier to get rid of.

… Tuesday, October 1, 2013 Summary Memorial Sloan Kettering researchers have discovered how a common bacterium can evolve to become more mobile and easier to get rid of. VIDEO | 00:14 The Social Behavior of Bacteria Offers New Ideas for Antimicrobial Drug Design Video Details This movie clip shows Pseudomonas

Memorial Sloan Kettering’s 37th annual academic Convocation and the fifth Louis V. Gerstner Graduate School of Biomedical Sciences Commencement shared the spotlight on May 19.

… Tuesday, July 5, 2016 An afternoon ceremony on May 19 celebrated MSK’s 37th annual Convocation and the fifth Louis V. Gerstner Graduate School of Biomedical Sciences Commencement. Presided over by MSK President and CEO Craig Thompson , it recognized students who conducted their doctoral dissertation

Memorial Sloan Kettering Cancer Center (MSK), The Rockefeller University and Weill Cornell Medicine announced today that they have established a new drug discovery company called Bridge Medicines. Launched in partnership with Takeda Pharmaceutical Company Ltd. and healthcare investment firms Bay City Capital and Deerfield Management, Bridge Medicines is a groundbreaking initiative that completes a seamless, fully funded and professionally staffed path from concept to drug candidate to efficiently and rapidly develop innovative therapeutics for treating human diseases.

… Monday, October 31, 2016 Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine announced today that they have established a new drug discovery company called Bridge Medicines. Launched in partnership with Takeda Pharmaceutical Company Ltd. and healthcare investment

Learn how our donor community is supporting MSK research and education.

… Thursday, April 1, 2021 Every day, your dollars are accelerating today’s most daring discoveries straight into lifesaving care. Read more to learn about your impact. The Society of Memorial Sloan Kettering Winter Lunch On February 3, The Society of MSK hosted its eighth annual Winter Lunch to support

A prominent research grant will enable MSK doctors and scientists to advance the treatment of bladder cancer.

… Friday, May 31, 2019 Summary The National Cancer Institute recently awarded MSK a prestigious SPORE grant for bladder cancer research. Learn about how MSK researchers will use the $6.5 million award to gain insights into how the disease develops and responds to treatment. Bladder cancer is the fifth

Several types of cancer were once strongly linked to an AIDS diagnosis. Thanks to improved HIV medications, that's changing.

… Wednesday, April 3, 2019 Summary People with HIV are sometimes susceptible to getting specific types of cancer. This association has changed over the years, as drugs to control HIV infection have become available. When the AIDS epidemic began in 1981, many of the first reported cases were young gay men

A drug combination that halts tumor cell division can stir the immune system into taking action.

… Thursday, December 20, 2018 Summary According to scientists at the Sloan Kettering Institute, a two-drug combination that doesn’t directly kill tumor cells can still help as a cancer treatment. The key is activating the immune system. The goal of most cancer-fighting drugs is to kill tumor cells. But

In what is being hailed as a watershed moment for both cancer care and biotechnology, the US Food and Drug Administration has approved a personalized, cell-based immunotherapy for use in children and young adults with blood cancer. For more information or to arrange interviews, e-mail Caitlin Hool at [email protected].

… Tuesday, September 5, 2017 The FDA has approved a new type of immunotherapy called chimeric antigen receptor (CAR) T cell therapy . In this approach, scientists genetically engineer a patient’s own immune cells to make a new protein that can latch onto cancer. This turns them into supercharged cancer

Structural biologists in the Sloan Kettering Institute have used a powerful tool called cryo-EM to solve the structure of a major cancer player.

… Wednesday, December 13, 2017 Summary Researchers in the Sloan Kettering Institute have solved the structure of an important signaling molecule in cancer cells. They used a new technology called cryo-EM to visualize the structure in three dimensions. The detailed information provided by this image paves